山东大学耳鼻喉眼学报 ›› 2022, Vol. 36 ›› Issue (2): 72-77.doi: 10.6040/j.issn.1673-3770.0.2021.121
王惠1, 王俊2,孙乙1,于腾飞1,朱玉广2, 朱艳2
WANG Hui1, WANG Jun2, SUN Yi1, YU Tengfei1, ZHU Yuguang2, ZHU Yan2
摘要: 目的 观察玻璃体腔注射肝细胞生长因子基因修饰的人脐带间充质干细胞(HGF-MSCs)对糖尿病大鼠视网膜组织肝细胞生长因子(HGF)表达的影响,探讨HGF-MSCs对大鼠Ⅱ型糖尿病性视网膜病变的作用。 方法 体外分离、培养人脐带间充质干细胞(hUCMSCs)并鉴定。采用感染复数值(MOI)50的慢病毒载体转染hUCMSCs。4周龄SD雄性大鼠,按照随机数字表法分为正常组(8只),糖尿病组(60只),糖尿病组又分为糖尿病对照组、PBS 组、MSCs组和 HGF-MSCs组(每组15只)。 糖尿病组大鼠采用腹腔注射链脲佐菌素(STZ)建立糖尿病大鼠模型。建模3个月后对糖尿病组进行后续实验。糖尿病对照组不行特殊治疗,PBS 组玻璃体腔注射磷酸盐缓冲液,MSCs组玻璃体腔注射hUCMSCs,HGF-MSCs组玻璃体腔注射HGF-MSCs。干预2、4、6周后行荧光定量PCR检测大鼠视网膜组织HGF mRNA的表达;Western blot检测大鼠视网膜组织HGF的表达。 结果 培养的脐带间充质干细胞可以诱导分化为成骨细胞、成脂肪细胞。MOI 50 的慢病毒成功转染hUCMSCs。大鼠视网膜荧光定量PCR和Western blot结果显示:在同一时间点,与其他组相比,正常组大鼠视网膜的HGF及其 mRNA的表达明显降低,差异具有统计学意义(P<0.05)。在同一时间点,与其他组相比,HGF-MSCs组大鼠视网膜的HGF 及其mRNA的表达明显增加,差异具有统计学意义(P<0.05)。不同时间点各组大鼠视网膜HGF 及其mRNA的表达差异没有统计学意义(P>0.05)。 结论 糖尿病大鼠视网膜HGF 及其mRNA的表达增加。单纯玻璃体腔注射hUCMSCs,不影响糖尿病大鼠视网膜HGF 及其mRNA的表达。玻璃体腔注射HGF修饰的hUCMSCs,可以促进糖尿病大鼠视网膜HGF 及其mRNA的表达,可能与HGF相互作用减轻糖尿病视网膜病变的早期病变发展。
中图分类号:
[1] 周玮琰, 王洪亚, 杜秀娟, 等. 甘糖酯对糖尿病大鼠视网膜病变中血管生成因子VEGF表达的影响[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 90-95. doi: 10.6040/j.issn.1673-3770.0.2016.146. ZHOU Weiyan, WANG Hongya, DU Xiujuan, et al. Effects of PGMS on the expression of vascular endothelial growth factor in the rat of diabetic retinopathy[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2017, 31(2): 90-95. doi: 10.6040/j.issn.1673-3770.0.2016.146. [2] Sun JK, Jampol LM. The diabetic retinopathy clinical research network(DRCR.net)and its contributions to the treatment of diabetic retinopathy[J]. Ophthalmic Res, 2019, 62(4): 225-230.doi:10.1159/000502779. [3] Tang PH, Hariprasad SM, Do DV. Rethinking management strategies for proliferative diabetic retinopathy[J]. Ophthalmic Surg Lasers Imaging Retina, 2018, 49(4): 224-227. doi:10.3928/23258160-20180329-01. [4] Capitão M, Soares R. Angiogenesis and inflammation crosstalk in diabetic retinopathy[J]. J Cell Biochem, 2016, 117(11): 2443-2453. doi:10.1002/jcb.25575. [5] Ezquer M, Urzua CA, Montecino S, et al. Intravitreal administration of multipotent mesenchymal stromal cells triggers a cytoprotective microenvironment in the Retina of diabetic mice[J]. Stem Cell Res Ther, 2016, 7: 42. doi:10.1186/s13287-016-0299-y. [6] Wang LS, Wang H, Zhang QL, et al. Hepatocyte growth factor gene therapy for ischemic diseases[J]. Hum Gene Ther, 2018, 29(4): 413-423. doi:10.1089/hum.2017.217. [7] Country MW. Retinal metabolism: a comparative look at energetics in the Retina[J]. Brain Res, 2017, 1672: 50-57. doi:10.1016/j.brainres.2017.07.025. [8] 刘万智, 陈珺, 樊长春. 康柏西普治疗增生性糖尿病视网膜病变[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 88-91. doi: 10.6040/j.issn.1673-3770.0.2018.005. LIU Wanzhi, CHEN Jun, FAN Changchun. Clinical study of conbercept in the treatment of proliferative diabetic retinopathy[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(6): 88-91. doi: 10.6040/j.issn.1673-3770.0.2018.005. [9] El Rami H, Barham R, Sun JK, et al. Evidence-based treatment of diabetic retinopathy[J]. Semin Ophthalmol, 2017, 32(1): 67-74. doi:10.1080/08820538.2016.1228397. [10] Baker CW, Jiang Y, Stone T. Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network[J]. Curr Opin Ophthalmol, 2016, 27(3): 210-216. doi:10.1097/icu.0000000000000262. [11] Hammes HP, Lin J, Renner O, et al. Pericytes and the pathogenesis of diabetic retinopathy[J]. Diabetes, 2002, 51(10): 3107-3112. doi:10.2337/diabetes.51.10.3107. [12] Yun JH, Park SW, Kim KJ, et al. Endothelial STAT3 activation increases vascular leakage through downregulating tight junction proteins: implications for diabetic retinopathy[J]. J Cell Physiol, 2017, 232(5): 1123-1134. doi:10.1002/jcp.25575. [13] Yun JH, Koh YJ, Jeong HS, et al. Propranolol increases vascular permeability through pericyte apoptosis and exacerbates oxygen-induced retinopathy[J]. Biochem Biophys Res Commun, 2018, 503(4): 2792-2799. doi:10.1016/j.bbrc.2018.08.041. [14] Yun JH. Hepatocyte growth factor prevents pericyte loss in diabetic retinopathy[J]. Microvasc Res, 2021, 133: 104103. doi:10.1016/j.mvr.2020.104103. [15] Miyagi H, Thomasy SM, Russell P, et al. The role of hepatocyte growth factor in corneal wound healing[J]. Exp Eye Res, 2018, 166: 49-55. doi:10.1016/j.exer.2017.10.006. [16] Cantón A, Burgos R, Hernández C, et al. Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy[J]. Br J Ophthalmol, 2000, 84(7): 732-735.doi:10.1136/bjo.84.7.732. [17] Nowak M, Wielkoszyński T, Marek B, et al. A comparison of the levels of hepatocyte growth factor in serum in patients with type 1 diabetes mellitus with different stages of diabetic retinopathy[J].Endokrynologia Polska, 2008, 59(1): 2-5. [18] Simó R, Vidal MT, García-Arumí J, et al. Intravitreous hepatocyte growth factor in patients with proliferative diabetic retinopathy: a case-control study[J]. Diabetes Res Clin Pract, 2006, 71(1): 36-44.doi:10.1016/j.diabres.2005.05.017. [19] Yun JH. Hepatocyte growth factor prevents pericyte loss in diabetic retinopathy[J]. Microvasc Res, 2021, 133: 104103. doi:10.1016/j.mvr.2020.104103. [20] Zakirova EY, Valeeva AN, Aimaletdinov AM, et al. Potential therapeutic application of mesenchymal stem cells in ophthalmology[J]. Exp Eye Res, 2019, 189: 107863. doi:10.1016/j.exer.2019.107863. [21] Jin ZB, Gao ML, Deng WL, et al. Stemming retinal regeneration with pluripotent stem cells[J]. Prog Retin Eye Res, 2019, 69: 38-56. doi:10.1016/j.preteyeres.2018.11.003. [22] Xu W, Wang XT, Xu GX, et al. Stromal cell-derived factor 1α-stimulated mesenchymal stem cells confer enhanced protection against light-induced retinal degeneration in rats[J]. Curr Eye Res, 2014, 39(1): 69-78. doi:10.3109/02713683.2013.824988. [23] Deng W, Obrocka M, Fischer I, et al. In vitro differentiation of human marrow stromal cells into early progenitors of neural cells by conditions that increase intracellular cyclic AMP[J]. Biochem Biophys Res Commun, 2001, 282(1): 148-152. doi:10.1006/bbrc.2001.4570. [24] Kim KS, Park JM, Kong T, et al. Retinal angiogenesis effects of TGF-β1 and paracrine factors secreted from human placental stem cells in response to a pathological environment[J]. Cell Transplant, 2016, 25(6): 1145-1157. doi:10.3727/096368915x688263. [25] Mathot F, Shin AY, Van Wijnen AJ. Targeted stimulation of MSCs in peripheral nerve repair[J]. Gene, 2019, 710: 17-23. doi:10.1016/j.gene.2019.02.078. [26] Hei WH, Almansoori AA, Sung MA, et al. Adenovirus vector-mediated ex vivo gene transfer of brain-derived neurotrophic factor(BDNF)tohuman umbilical cord blood-derived mesenchymal stem cells(UCB-MSCs)promotescrush-injured rat sciatic nerve regeneration[J]. Neurosci Lett, 2017, 643: 111-120. doi:10.1016/j.neulet.2017.02.030. [27] Fotia C, Massa A, Boriani F, et al. Prolonged exposure to hypoxic milieu improves the osteogenic potential of adipose derived stem cells[J]. J Cell Biochem, 2015, 116(7): 1442-1453.doi:10.1002/jcb.25106. [28] El Barky AR, Ezz AAH, Alm-Eldeen AA, et al. Can stem cells ameliorate the pancreatic damage induced by streptozotocin in rats? [J]. Can J Diabetes, 2018, 42(1): 61-70. doi:10.1016/j.jcjd.2017.04.002. [29] Choi KS, Shin JS, Lee JJ, et al. In vitro trans-differentiation of rat mesenchymal cells into insulin-producing cells by rat pancreatic extract[J]. Biochem Biophys Res Commun, 2005, 330(4): 1299-1305.doi:10.1016/j.bbrc.2005.03.111. |
[1] | 王娇娇,李苗宋宗明. 糖尿病视网膜病变的机制和细胞模型研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 93-99. |
[2] | 刘志高,王淑雅,韩旭光,王玉,李志伟,马爱华,赵博军. 增殖性糖尿病视网膜病变术前玻璃体腔应用阿柏西普的时机及其疗效观察[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 99-103. |
[3] | 刘建波,张环. 超声乳化联合玻璃体腔药物注射治疗白内障合并糖尿病性黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 99-104. |
[4] | 李宝华,刘平,王新. β-榄香烯影响糖尿病大鼠视网膜中IL-1β、ICAM-1表达分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 111-114. |
[5] | 刘万智,陈珺,樊长春. 康柏西普治疗增生性糖尿病视网膜病变[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 88-91. |
[6] | 周学义,李一鸣,王美菊,张苑苑,张历浊. 25+微创玻璃体视网膜手术联合玻璃体腔注射雷珠单抗治疗增生型糖尿病视网膜病变的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 87-89. |
[7] | 周玮琰,王洪亚,杜秀娟,董卫红. 甘糖酯对糖尿病大鼠视网膜病变中血管生成因子VEGF表达的影响[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 90-95. |
[8] | 严晓腾,冯军,康欣乐. 玻璃体腔注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床观察[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 105-108. |
[9] | 邵娜,张晗. 糖尿病患者行白内障超声乳化术后视力及眼底的变化[J]. 山东大学耳鼻喉眼学报, 2016, 30(1): 83-87. |
[10] | 李俊英. 瑞舒伐他汀联合非诺贝特对老年糖尿病视网膜病变患者血管内皮功能的影响[J]. 山东大学耳鼻喉眼学报, 2015, 29(5): 72-75. |
[11] | 刘志高, 颜世龙, 胡尊霞, 孙同鑫, 杨明, 王玉. 济南市农村白内障患者糖尿病及糖尿病视网膜眼底病变患病率调查分析[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 38-39. |
[12] | 刘海洋, 李甦雁, 张正培, 范巍. 改良膜分割与双手膜清除技术在23G玻璃体手术治疗增殖性糖尿病视网膜病变中的对比[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 52-55. |
[13] | 马栋, 郭承伟. 络治法对STZ诱导的糖尿病大鼠视网膜血管消化铺片中VCAM-1表达的影响[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 64-68. |
[14] | 刘蓓1,朱忠桥1,杜善双1,王丽丽2,杨新光1. 前期激光及曲安奈德应用对增殖性糖尿病视网膜病变玻璃体切割手术的影响[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 66-68. |
[15] | 王淑雅,华宁,李筱荣 . 糖尿病性盲患者玻璃体手术后的脱盲率及未脱盲原因分析 [J]. 山东大学耳鼻喉眼学报, 2011, 25(6): 77-79. |
|